These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20935269)

  • 1. PSA kinetics: no substitute for annual biopsy in prostate cancer surveillance?
    Schmidt C
    J Natl Cancer Inst; 2010 Oct; 102(20):1533-5. PubMed ID: 20935269
    [No Abstract]   [Full Text] [Related]  

  • 2. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer.
    Whitson JM; Porten SP; Hilton JF; Cowan JE; Perez N; Cooperberg MR; Greene KL; Meng MV; Simko JP; Shinohara K; Carroll PR
    J Urol; 2011 May; 185(5):1656-60. PubMed ID: 21419438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invited commentary: Prostate cancer: doing less might be more. Comment on "Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer".
    Ablin RJ; Sartor O; Bennett CL
    Arch Intern Med; 2010 Aug; 170(15):1397-9. PubMed ID: 20696969
    [No Abstract]   [Full Text] [Related]  

  • 4. [The density of prostate specific antigen of the transition zone as an early predictor of prostate cancer].
    Topuzov ME; Prialukhin AE; Zhivov AV; Plekhanov AIu
    Vestn Khir Im I I Grek; 2008; 167(6):119-21. PubMed ID: 19241832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New tests for prostate cancer.
    O'Hanlon LH
    J Natl Cancer Inst; 2013 Nov; 105(22):1672-4. PubMed ID: 24198330
    [No Abstract]   [Full Text] [Related]  

  • 6. [What does "PSA recurrence mean? "Active surveillance" for all risk groups is an option].
    Hautmann R
    Urologe A; 2006 Oct; 45(10):1239. PubMed ID: 17006696
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention.
    Klotz L
    Nat Clin Pract Urol; 2008 Jan; 5(1):2-3. PubMed ID: 18043601
    [No Abstract]   [Full Text] [Related]  

  • 9. The PSA era is not over for prostate cancer.
    Catalona WJ; Loeb S
    Eur Urol; 2005 Oct; 48(4):541-5. PubMed ID: 16139417
    [No Abstract]   [Full Text] [Related]  

  • 10. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
    Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
    Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF; Mensink HJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
    J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
    Klotz L
    Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prostate carcinoma: prostate-specific antigen--and then what?].
    Schmid HP
    Ther Umsch; 1998 Jul; 55(7):426-8. PubMed ID: 9702110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prostatic cancer--can unnecessary therapy be avoided? Prostate-specific antigens (PSA) kinetics can guide the management].
    Malmström PU
    Lakartidningen; 2006 Feb 1-7; 103(5):279. PubMed ID: 16512565
    [No Abstract]   [Full Text] [Related]  

  • 19. Breast metastasis from prostate cancer and interpretation of immunoreactivity to prostate-specific antigen.
    Cheng CW; Chan LW; Ng CF; Chan CK; Tse MK; Lai MM
    Int J Urol; 2006 Apr; 13(4):463-5. PubMed ID: 16734876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
    Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
    J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.